Recent investigations have focused on the convergence of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopamine neurotransmission. While GLP stimulators are widely employed for managing type 2 diabetes, their emerging impacts on mot